Information Technology

Mining and Metals

EMBARK: A Phase 3b, Open-label, Single-arm, Study to Evaluate the Long-term Safety and Efficacy of Aducanumab in Eligible Participants with Alzheimer’s Disease

Made public by

Biogen

sourced by PitchSend

1 of 20

Creator

Biogen

Category

Healthcare

Published

2020

Slides

Open in new tab

Open in new tab

Open in new tab

Open in new tab

Open in new tab

Open in new tab

Open in new tab

Open in new tab

Open in new tab

Open in new tab

Open in new tab

Open in new tab

Open in new tab

Open in new tab

Open in new tab

Open in new tab

Open in new tab

Open in new tab

Open in new tab

Transcriptions

#1 #2 #3 #4 #5 #6 #7 #8 #9 #10 #11 #12 #13 #14 #15 #16 #17 #18 #19

Download to PowerPoint

Download presentation as an editable powerpoint.

Related

Fiscal 3Q Investor Presentation image

Fiscal 3Q Investor Presentation

Healthcare

FY23 Full-Year Results Presentation image

FY23 Full-Year Results Presentation

Healthcare

Healthcare Network P&L Statement and Expansion Projects image

Healthcare Network P&L Statement and Expansion Projects

Healthcare

Accreditation and Quality Assurance Overview image

Accreditation and Quality Assurance Overview

Healthcare

Investment Highlights image

Investment Highlights

Healthcare

Investor Presentation image

Investor Presentation

Healthcare

IDEAYA Biosciences Interim IDE397 Phase 1 Clinical Data and Q1 2022 Corporate Update image

IDEAYA Biosciences Interim IDE397 Phase 1 Clinical Data and Q1 2022 Corporate Update

Healthcare

BioAtla Investor Presentation Deck image

BioAtla Investor Presentation Deck

Healthcare